Yang Hao Selected as Outstanding Enterprise Science and Technology Talents in Wucheng District
Release time:
2020-08-14
Yang Hao Selected as Outstanding Enterprise Science and Technology Talents in Wucheng District
News from our newspaper The People's Government of Wucheng District of Jinhua City recently announced the list of outstanding enterprise science and technology talents in Wucheng District in 2017 . Yang Hao, head of the research and development department of Jianfeng Health Technology Company, was selected.
"Excellent Enterprise Science and Technology Talents" is the People's Government of Wucheng District, Jinhua City, in order to deeply implement the strategy of "Talents Strong District", strive to create a good environment for gathering, cultivating and using talents, and form a benign talent training, introduction and use The operating mechanism creates a talent team with sufficient quantity, good quality, reasonable structure and complete categories, the selection, which provides strong talent and intellectual support for economic and social development, has been selected for 16 sessions so far. The talents who participate in the election generally have intermediate (including intermediate) or above titles or have senior (including senior) or above skills, and are engaged in scientific research, technological development, technological transformation, new product research and development, and make outstanding contributions in operation and management, resulting in significant economic and social benefits. For individuals who are rated as "outstanding enterprise scientific and technological talents", the Wucheng district government will issue honorary certificates and reward each person with yuan.
Since he became the head of the research and development department of Jianfeng Health Company, Yang Hao has been working around "transforming scientific and technological achievements into real productivity". In addition to undertaking the development of new products, optimization and innovation of old products in the three business sectors of health care products, Chinese herbal pieces and plant extracts, he is also responsible for the management of relevant government projects and intellectual property rights. In recent years, the research and development department has successfully realized the production, marketing and sales of ginkgo biloba extract, rhodiola extract, cranberry extract, cinnamon extract and wolfberry extract through technical research and innovative technical means. Ginkgo biloba extract in strict accordance with the laws and regulations, to achieve the national standard, low ginkgolic acid, low color, low solvent residue, no pesticide residue and other standards in line with the domestic and foreign pharmacopoeia standard series of products; Rhodiola extract in line with the quality requirements of export trade products; Cranberry extract to establish a characteristic spectrum identification detection technology, the first in the country to establish its unique A family proanthocyanidins component detection; cinnamon extract will have a certain damage to the human liver coumarin, the use of proprietary technology to remove, to ensure the safety of the product; wolfberry extract process can be prepared with a larger molecular weight of polysaccharide products, compared to ordinary products on the market to enhance the immune function is more significant. 2017 , the research and development department combined with market demand, using one or more reasonable formulas of cranberry extract, medlar extract, blueberry extract, grape seed extract, garlic extract, tomato extract and green tea extract to develop 3 plant solid drinks for women whitening, blood purification and men's pregnancy preparation.
In addition, Yang Hao also participated in the district-level agricultural key project "Pilot Process Research on Extraction of Natural High Efficiency Antioxidant ergothioneine from Mushrooms", which has applied for final acceptance. A municipal agricultural key project "Research on Industrialization Technology of Resveratrol and Its Oligomers Extraction from Grapevine" is currently under research and development. Both projects use agricultural waste as raw materials to extract bioactive substances, which can comprehensively utilize agricultural resources and have high economic and social benefits. (Xu Feng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page